Antimicrobial susceptibility testing (AST) is a laboratory procedure done by clinical laboratory professionals to identify which antimicrobial specimen is specifically effective for individual patients. The antimicrobial susceptibility testing market consists of sales of antimicrobial susceptibility testing by entities (organizations, sole traders and partnerships) that are engaged in laboratory services that provide antimicrobial susceptibility testing. The main types of antimicrobial susceptibility testing (AST) procedures are antibacterial testing, antifungal testing, antiparasitic testing and others. Antifungal susceptibility testing refers to the ability of a specific organism to grow in vitro in the presence of a particular drug. AST products that are used in the testing are manual antimicrobial susceptibility testing products, automated laboratory instruments, and other consumables. These are used for diagnostics, drug discovery and development, and epidemiology. Antimicrobial susceptibility testing is used by hospitals and diagnostic centres, pharmaceutical and biotechnology companies, research and academic institutes, and clinical research organizations (CROs). The antimicrobial susceptibility testing market research report is one of a series of new reports from The Business Research Company that provides antimicrobial susceptibility testing market statistics, including antimicrobial susceptibility testing industry global market size, regional shares, competitors with an antimicrobial susceptibility testing market share, detailed antimicrobial susceptibility testing market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial susceptibility testing industry. This antimicrobial susceptibility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antimicrobial susceptibility testing market size grew from $3.67 billion in 2022 to $3.91 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antimicrobial susceptibility testing market size is expected to grow to $4.94 billion in 2027 at a CAGR of 6.0%. The rising incidence of infectious diseases globally contributed to the growth of the antimicrobial susceptibility testing market. Infectious diseases are caused by organisms like bacteria, viruses, fungi and parasites. Diseases caused by bacteria are bacterial pneumonia, tuberculosis, the virus smallpox, AIDS and others. According to World Health Organization (WHO), in 2021, , an estimated 10.6 million people are infected with tuberculosis globally, 1.6 million died , and 1.5 million people acquired HIV in 2021 while 650,000 people lost lives due to it. This increase in the incidence of infected people boosted the use of susceptibility testing of the organisms to develop the most effective drugs and this, in turn, drove the market for antimicrobial susceptibility testing. Rapid antimicrobial susceptibility testing is increasingly being used to avoid misuse of antibiotics and to provide effective treatment and this is emerging as a key trend in the antimicrobial susceptibility testing market. There are many ways to perform antimicrobial susceptibility testing in minutes or a few hours. FISH (Fluorescence in situ hybridization) is mostly used in rapid antimicrobial susceptibility testing. The PNA-FISH applies peptide nucleic acid probes that allow rapid and specific binding, this process is applied in QuickFish technology (OpGen) which performs identification of microbial by targeting 16s RNA. For instance, the antimicrobial susceptibility testing system by Genefluidics Inc measures bacterial growth by quantifying 16s rRNA molecules using an electrochemical biosensor. Major players in the antimicrobial susceptibility testing market are BioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Accelerate Diagnostics, Hi-Media Laboratories, Creative Diagnostics, Merck KGaA, Roche Diagnostics Limited, BD, Alifax Holding S.p.A., Synbiosis, Zhuhai DL Biotech Co, Mast Group, ELITechGroup, Genefluidics, Mast Group, CONDALAB, and QuantaMatrix. North America was the largest region in the antimicrobial susceptibility testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the antimicrobial susceptibility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antimicrobial susceptibility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimicrobial susceptibility testing (AST) market includes revenues earned by dilution susceptibility tests and disc diffusion susceptibility tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antimicrobial susceptibility testing market is segmented - 1) By Type: Antibacterial Testing, Antifungal Testing, Antiparasitic Testing, Other Types 2) By Products: Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, Consumables 3) By Application: Diagnostics, Drug Discovery and Development, Epidemiology, Other Applications 4) By End User: Hospitals And Diagnostic Centers, Pharmaceutical And Biotechnology Companies, Research And Academic Institutes, Clinical Research Organizations (CROs)

Chemicals are used in antimicrobial coatings to prevent pathogen growth by disrupting cellular membranes. In other words, an antimicrobial coating is a chemical substance that is applied to a surface to prevent disease-causing microorganisms from growing. These coatings not only improve the surface's durability, appearance, corrosion resistance, and so on, but they also protect it against disease-causing bacteria. The main types of antimicrobial medical device coatings are metallic coatings and non-metallic coatings. Metallic coatings contain a metallic element or alloy and are applied on devices or equipment for protection against corrosion, sunlight, and oxidation. Metallic coatings consist of silver coatings, copper coatings, and other metallic coatings. Non-metallic coatings can be added to metallic coatings to produce effective wear-resistant coatings. The different types of devices include catheters, implantable devices, surgical instruments, and others. It is implemented in areas such as orthopedics, general surgery, dentistry, cardiovascular, gynecology, and others and is used in hospitals, diagnostic centers, and ambulatory surgical centers. The antimicrobial medical device coatings market research report is one of a series of new reports from The Business Research Company that provides antimicrobial medical device coatings market statistics, including antimicrobial medical device coatings industry global market size, regional shares, competitors with an antimicrobial medical device coatings market share, detailed antimicrobial medical device coatings market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial medical device coatings industry. This antimicrobial medical device coatings market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antimicrobial medical device coatings market size grew from $2.1 billion in 2022 to $2.43 billion in 2023 at a compound annual growth rate (CAGR) of 16.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The antimicrobial medical device coatings market size is expected to grow to $4 billion in 2027 at a CAGR of 13.2%. The rising cardiovascular diseases drive the growth of the antimicrobial medical device coatings market over the coming years. CVDs (cardiovascular diseases) are a category of heart and blood vessel problems. Cardiovascular diseases (CVDs) are the primary, source of death worldwide with low- and middle-income nations accounting for three-quarters of CVD deaths. Antimicrobial coated cardiovascular devices are used for the treatment of cardiovascular diseases and disorders. According to the World Health Organization (WHO) report in 2021, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths. Heart attacks and strokes were responsible for 85% of these deaths. The growing technological advancements are shaping the antimicrobial medical device coating market. Major companies operating in the antimicrobial medical device coating sector are focused on developing technological solutions for antimicrobial medical device coatings to prevent the spread of viruses. For instance, in November 2020, Zonitise Ltd., a UK-based biotech firm, introduced an antimicrobial surface treatment based on nanotechnology that has been shown to destroy hazardous viruses and bacteria for up to twelve months after one application, including TGEV COVID-19, the model virus for SARS COV 2. This coating not only disinfects surfaces but also protects them in an antimicrobial sealant that destroys and prevents the formation of any hazardous bacteria that come into touch with it for up to twelve months. In February 2021, Bain Capital, a US-based investment firm, and Cinven, a UK-based private equity firm acquired Lonza Specialty Ingredients (LSI), a division of Lonza AG for $4.7 billion. Through this acquisition, LSI provides a range of differentiated specialty chemical products, underpinned by strong R&D capabilities, regulatory and IP protections, and a highly qualified and dedicated workforce. Lonza Specialty Ingredients (LSI) is a US-based company that specializes in microbial control for personal care as well as mold and other potential pathogen prevention in homes, schools, workplaces, and the environment. Major players in the antimicrobial medical device coatings market are AST Products Inc., BioInteractions Ltd., Covalon Technologies Ltd., Royal DSM, Hydromer, BASF SE, Sciessent LLC, DuPont de Nemours Inc., Kraton Corporation, Sono-Tek Corporation, and Microban International. North America was the largest region in the antimicrobial medical device coatings market in 2022. Europe was the second-largest market in the antimicrobial medical device coatings market. The regions covered in the antimicrobial medical device coatings market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antimicrobial medical device coatings market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimicrobial medical device coatings market consists of sales of non-metallic antimicrobial medical device coating including polymeric and organic coatings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antimicrobial medical device coatings market is segmented - 1) By Type of Material: Metallic Coatings, Non Metallic Coatings 2) By Device Type: Catheters, Implantable Devices, Surgical Instruments, Other Device Types 3) By Application: Orthopedics, General Surgery, Dentistry, Cardiovascular, Gynecology, Other Applications 4) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers

Veterinary services refers to various tests conducted for diagnosis of infectious agents, toxins, and other causes of diseases in animals. The main technologies of veterinary laboratory testing services are clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and other technologies. Clinical Biochemistry is the branch of laboratory medicine concerned with the detection of chemicals (both natural and synthetic) in blood, urine, and other bodily fluids. These veterinary laboratory testing services are beneficial for pet animals and livestock and are used by veterinary hospitals and clinics, diagnostic laboratories, research institutes, in-house testing, and other end users. The veterinary laboratory testing services research report is one of a series of new reports from The Business Research Company that provides veterinary laboratory testing services statistics, including veterinary laboratory testing services industry global market size, regional shares, competitors with veterinary laboratory testing services share, detailed veterinary laboratory testing services segments, market trends and opportunities, and any further data you may need to thrive in the veterinary laboratory testing services industry. This veterinary laboratory testing services research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry. The global veterinary laboratory testing services market size will grow from $23.39 billion in 2022 to $25.75 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary laboratory testing services market size is expected to grow from $36.19 billion in 2027 at a CAGR of 8.9%. The veterinary laboratory testing services market is being driven by the rising prevalence of disease epidemics in animals. For instance, cattle are getting infected by a wide group of pathogens, which is leading to a rise in the number of laboratory tests done for cattle. Moreover, livestock globally is becoming vulnerable to infectious diseases caused by pathogens and viruses. For instance, Salmonella and Campylobacter are the two most common zoonotic pathogens that are present in the intestine tracts of animals, such as chickens, swine, and cattle, and are leading causes of foodborne disease worldwide. These diseases get passed through the food chain to humans, which is a potential threat. Therefore, efforts to curb these infections in animals are driving the market for veterinary laboratory testing. The FoodNet system (Center for Disease Control and Prevention, USA) identified 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths. The highest incidences per 100,000 people were for Campylobacter, Salmonella, and Shigella(these are organisms causing bacterial gastroenteritis, which is a digestive problem) in the USA. The veterinary laboratory testing services market is being restrained by a lack of animal healthcare awareness in emerging markets, which is responsible for causing many animal-related diseases to go untreated. Some of the ry laboratory testing services market is being restrained by a lack of animal healthcare awareness in emerging markets, which is responsible for causing many animal-related diseases to go untreated. Some of the illnesses in animals are often unknown or undiagnosed due to a lack of awareness. For instance, in emerging countries like India, China, and South Africa, diseases like rabies, which can be detected through veterinary testing, are often left undiagnosed, which results in the deaths of a large number of people who are bitten by rabid animals in these countries. For example, more than 55,000 people globally die of rabies every year, and around 30,000 of these cases are from India. According to Prof Andrew Leisewitz from the University of Pretoria, around 27,000 cases of animal rabies were reported, but the estimated number of actual cases was much higher. Such a lack of awareness, especially in emerging markets, is restraining the veterinary laboratory testing services market. The companies in the veterinary laboratory testing services are increasingly adopting multiple testing panels. A test panel is a pre-decided group of medical tests to be used in the diagnosis as well as the treatment of an animal disease. The test panels are normally composed of individual laboratory tests, which are grouped by specimen type, the methodology used, or by the most frequently requested tests. Multiple test panels offer various advantages, such as labour efficiency, automation, and reduced costs, achieved by conducting a large number of tests daily. For instance, Abaxis Inc. is using multiple single-use test panels designed to address several conditions, wherein just 3 to 4 drops of blood are required to deliver up to 14 precise results. The veterinary laboratory testing market in the US is subject to regulations by the Center for Disease Control and Prevention (CDC). The CDC requires the professionals responsible for conducting the tests to undergo technical training at the National Veterinary Services Laboratories (NVSL). The veterinary laboratory personnel are required to conduct the tests licenced by the United States Department of Agriculture(USDA) as per the label instructions or the official protocols provided by the NVSL. Further, the CDC requires the laboratory personnel to test only those samples submitted by accredited veterinarians and report the test results within 48 hours of completion. Laboratory inspections must be conducted by animal health officials periodically. In February 2020, Zoetis, Inc., a US-based animal health company specializing in the discovery, development, production, and marketing of animal health drugs, acquired Ethos Diagnostic Science for an undisclosed amount. Through this acquisition, Zoetis continues to expand its diagnostics presence in order to provide American veterinarians with comprehensive services at an improved value. Ethos Diagnostic Science is a US-based veterinary diagnostic company pioneering in various types of diagnostic testing and clinical chemistry. Major players in the veterinary laboratory testing market are ABAXIS, Inc., IDEXX Laboratories, Inc., Heska Corporation, Pfizer Animal Health, Neogen Corporation, Thermo Fisher Scientific Inc., Zoetis, Inc., IDVet, Virbac, Zoetis, VCA Antech, Inc., and Prionics AG. North America was the largest region in the veterinary laboratory testing market in 2022. Asia-Pacific was the second-largest region in the global veterinary laboratory testing market. The regions covered in the global veterinary laboratory testing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary laboratory testing services market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The veterinary laboratory testing services market consists of revenues earned by entities that use technologies such as clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others for the diagnosis of animal diseases. The tests conducted involve chemistry, pathology, serology, radiography and endocrinology related assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary laboratory testing services market is segmented - 1) By Technology: Clinical Biochemistry, Immunodiagnostics, Hematology, Molecular Diagnostics, Urinalysis, Other Technologies 2) By Animal Type: Pet Animals, Livestock 3) By End User: Veterinary Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, In-House Testing, Other End Users

Veterinary patient monitoring equipment refers to a type of devices and instruments that continuously track and record changes in patient wellbeing, monitor animals' respiration, blood pressure, and other vital signs, and provide warning systems. These systems are used to continuously monitor the animals to detect diseases at early stages to prevent any risks. The main types of veterinary patient monitoring equipment are cardiac monitoring devices, respiratory monitoring devices, remote patient monitoring devices, multi-parameter monitoring devices, neuromonitoring devices, and other products. The cardiac monitoring devices refer to the devices that deal with animal cardiac diseases. These are used for animals such as small companion animals, large companion animals, wild animals, zoo animals, aquatic animals, and exotic animals. Veterinary patient monitoring equipment is used in veterinary hospitals, veterinary clinics, and veterinary research centers. The veterinary patient monitoring equipment research report is one of a series of new reports from The Business Research Company that provides veterinary patient monitoring equipment statistics, including veterinary patient monitoring equipment industry global market size, regional shares, competitors with veterinary patient monitoring equipment shares, detailed veterinary patient monitoring equipment segments, market trends and opportunities, and any further data you may need to thrive in the veterinary patient monitoring equipment industry. This veterinary patient monitoring equipment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global veterinary patient monitoring equipment market size will grow from $0.42 billion in 2022 to $0.45 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary patient monitoring equipment market size is expected to grow from $0.58 billion in 2027 at a CAGR of 6.4%. An increase in the prevalence rate of diseases among animals serves as one of the major drivers for the veterinary patient monitoring equipment market. An increase in the incidence of diseases in livestock and companion animals will require monitoring equipment to diagnose the diseases in animals. For instance, according to the Banfield Pet Hospital's 2020 Veterinary Emerging Topics (VET) Report, more than 50% of the dogs at 1,000 hospitals in 2019 were overweight or obese. Overweight pets are more likely to suffer from joint disease, respiratory disease, and other preventable conditions. The increase in the prevalence rate of diseases for animals results in an increased demand for enhanced veterinary patient monitoring equipment. Veterinary patient monitoring equipment is highly expensive. The cost of equipment will be a significant expense for a veterinary clinic or hospital. For instance, the average wearable device ranges from $50 to $100 and will likely have a recurring software as a service (SaaS) fee to store and retrieve an animal’s health data analytics. These expenses hinder the growth of the veterinary patient monitoring equipment market. Veterinarians and pet or cattle owners are shifting to wearable technology to keep track of animal behavior. Wearable technology is smart electronic devices that are worn on the body or integrated with clothing or accessories and monitor body temperature, behavior, and movement. These wearable monitoring devices provide timely insights regarding the overall health of the animal and help the veterinarian provide an appropriate diagnosis for the animal. For instance, Vetrax, a wearable sensor worn on a dog’s collar, enables clinicians and pet owners to monitor aspects of an animal’s behaviour when they are unsupervised. According to a report by Veterinary Practice News, 83% of pet owners are satisfied with the use of wearable technology and 68% find it an effective way of monitoring the weight and diabetes of their pets. The veterinary patient monitoring equipment market is regulated by government agencies such as the European Medicines Agency (EMA), USFDA (the US Food and Drug Administration), and others. The EMA should certify the medical devices before they are marketed. The EMA verifies the safety and quality of the devices before they can be certified and approved for use throughout the European Union. The EMA requires all devices to comply with the regulations stated under Directive 2001/82/EC and Regulation (EC) No. 726/2004. In August 2020, Merck Animal Health, a US-based company specializing in veterinary products, technologies, and services, acquired IdentiGEN Ltd. for an undisclosed amount. Through this acquisition, Merck offers animal monitoring for food producers, processors, and retailers who are searching for precise and comprehensive animal traceability solutions that offer full accountability as well as increased transparency, food quality, and sustainability for consumers. In combination with Merck's current identification and monitoring technology, which provides real-time, actionable data and insights to aid in, improve, or enhance animal management and health outcomes, the addition of specialized digital technology to our portfolio of medications, vaccines, and services offers comprehensive solutions to help advance animal health. IdentiGEN Ltd. is a land-based company pioneering in DNA-based analysis and diagnostics for animal health monitoring. Major players in the veterinary patient monitoring market are Smiths Group plc; Hallowell Engineering & Manufacturing Corporation; DRE Veterinary; Digicare Biomedical Technology Inc.; Midmark Corporation; Medtronic PLC.; Jorgensen Laboratories; Vetland Medical Sales and Services LLC; Jorgen Kruuse A/S; Mila International Inc.; and Mindray Medical International Limited. North America was the largest region in the veterinary patient monitoring market in 2022. Asia-Pacific was the second-largest region in the global veterinary patient monitoring market. The regions covered in the global veterinary patient monitoring equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the veterinary anesthesia equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The veterinary patient monitoring equipment market consists of sales of bedside patient monitoring systems, renal patient monitoring devices, circulatory system patient monitoring devices, and obesity patient monitoring devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary patient monitoring equipment market is segmented - 1) By Product: Cardiac Monitoring Devices, Respiratory Monitoring Devices, Remote Patient Monitoring Devices, Multi-Parameter Monitoring Devices, Neuromonitoring Devices, Other Products 2) By End User: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Centers 3) By Animal: Small Companion Animals, Large Companion Animals, Wild Animals, Zoo Animals, Aquatic Animals, Exotic Animals

Veterinary antibiotics refer to a class of animal medications that are used to treat infectious disease in animals by killing microorganisms such as bacteria and parasites by inhibiting the growth of their cell walls to fight infections and diseases in animals caused by bacteria and improve the animals' health conditions. The main product types of veterinary antibiotics include anti-parasitic, anti-bacterial, non-steroidal anti-inflammatory drugs, and other products. Non-steroidal anti-inflammatory drugs (NSAIDs) act as a bridge between the production and activity of prostaglandins (enzymes) implicated in inflammation. Approved veterinary NSAIDs are used in companion animal care to reduce the pain and swelling linked with osteoarthritis in dogs and horses. The administration of veterinary antibiotics includes premixes, injections, oral powders, oral solutions, and other administrations used on farm animals and companion animals. The veterinary antibiotics research report is one of a series of new reports from The Business Research Company that provides veterinary antibiotics statistics, including veterinary antibiotics industry global market size, regional shares, competitors with veterinary antibiotics share, detailed veterinary antibiotics segments, market trends and opportunities, and any further data you may need to thrive in the veterinary antibiotics industry. The veterinary antibiotics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global veterinary antibiotics market size will grow from $1.86 billion in 2022 to $2.02 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary antibiotics market size is expected to grow to $2.7 billion in 2027 at a CAGR of 7.5%. An increase in the number of zoonotic diseases is driving the veterinary antibiotics market. Zoonotic diseases are infectious diseases caused by microscopic organisms, infections, and parasites that spread between animals and humans. Two of the most common zoonotic pathogens, salmonella and campylobacter, are present in the intestines of these animals. Zoonotic diseases are also a potential threat to humans as they get transferred through the food chain. A study conducted by the FoodNet (Centers for Disease Control and Prevention, USA) found that 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths are caused by zoonotic diseases. In addition, the highest incidences per 100,000 people in the USA are caused by infectious diseases such as campylobacter, salmonella, and shigella. Therefore, there is a need to diagnose these diseases in animals at an early stage, which is a major driver of the veterinary antibiotics market. The rising threat of antibiotic resistance is a major restraint for the veterinary antibiotics market. Antibiotic resistance in animals refers to the ability of a microbe to withstand the impact of an antibiotic that once successfully treated infections caused by the same type of microbe. This can be a result of using antibiotics more than the prescribed limit. In this regard, the European Union (EU) has approved various restrictions on veterinary antibiotics, including a ban on antibiotics for animals and prohibiting the usage of antimicrobials in food, which is restricting the growth of the veterinary antibiotics market. Increasing collaboration between companies is an emerging trend in the veterinary antibiotics market. Collaboration offers companies the opportunity to combine technologies and a wide range, more diversified products to work with, and it also improves the quality of the antibiotics and the speed at which they are produced. Therefore, companies in the veterinary antibiotics market are focusing on collaborations. For instance, in September 2022, GlobalVetLink, a US-based provider of software services and informatics solutions in the field of animals, collaborated with Veterinary Innovative Partners to install GlobalVetLink Compliance Assistant, a thorough SaaS platform developed to simplify animal health. The veterinary antibiotics prescription drugs market is regulated by Section 503(f) of the Food, Drug, and Cosmetic Act of FDA. According to this law, the veterinary antibiotic drug labels are mandated to include a caution statement that states that these drugs can only be used with the permission of a licenced veterinarian. The sale and use of antibiotic prescription drugs without a prescription is usually reported to the FDA and strict action is taken based on it. Hence, regulations such as these would regulate veterinary antibiotic manufacturers and sellers. Major players in the veterinary antibiotics market are Bayer AG, Boehringer Ingelheim GmbH, CevaSanteAnimale, Eli Lilly Company, ElanCo., Merck & Co., Sanofi, Virbac, Zoetis, and Crystal Pharma. North America was the largest region in the veterinary antibiotics market in 2022. Asia-Pacific was the second-largest region in the global veterinary antibiotics market. The regions covered in the global veterinary antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary antibiotics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The veterinary antibiotics market consists of sales of antivirals, antiprotozoals, antifungals, aminoglycosides, beta-lactams, fluoroquinolones, glycopeptides, and lipopeptides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary antibiotics market is segmented - 1) By Product: Anti-Parasitic, Anti-Bacterial, Non-Steroidal Anti-Inflammatory Drug, Other Products 2) By End User: Farm Animals, Companion Animals 3) By Administration: Premixes, Injections, Oral Powders, Oral Solutions, Other Administration

Veterinary medical equipment refers to types of medical devices and surgical equipment such as endoscopic systems, dental equipment, and veterinary telemetry services that are used for operations, therapy, keeping track of diagnoses and vitals, and enhancing animal care to slow down the progression of diseases. The main types of veterinary medical equipment are veterinary diagnostic equipment, veterinary anaesthesia equipment, veterinary patient monitoring equipment, and other veterinary medical equipment that is used for animals such as small companion animals, large animals, and other animals. Veterinary anaesthesia equipment refers to the equipment that is used for animals to provide anesthesia. The products used are instruments, equipment, and disposables. These are used in veterinary hospitals, veterinary clinics, and research institutes. The veterinary medical equipment research report is one of a series of new reports from The Business Research Company that provides veterinary medical equipment statistics, including veterinary medical equipment industry global market size, regional shares, competitors with veterinary medical equipment shares, detailed veterinary medical equipment segments, market trends and opportunities, and any further data you may need to thrive in the veterinary medical equipment industry. This veterinary medical equipment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global veterinary medical equipment market grew from $2.25 billion in 2022 to $2.42 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The veterinary medical equipment market is expected to grow from $3.15 billion in 2027 at a CAGR of 6.8%. The global economy is expected to go through a continued period of steady growth during the forecast period. The US economy showed steady growth during the historic period, and this is likely to continue during the forecast period. Emerging markets reached 4.8% in 2020 versus 3.6% in 2019. The continued economic growth is expected to contribute to increased standards of living of the global population and strengthen the presence of the middle class. Increased standards of living and a strengthened middle class will further drive the demand for improved nutrition, particularly animal protein, and increase focus on food quality and safety, supporting the growth of the animal medicine market in terms of feed additives. Thus, economic growth is expected to drive this market. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the veterinary medical equipment market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down" and the outbreak hurting businesses throughout 2020 and into 2021. However, it is expected that the veterinary medical equipment market will recover from the shock across the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. Advances in diagnostic tools have improved veterinary services. Equipment such as portable x-ray and portable ultrasound scanners has increased the efficiency of veterinary treatment (especially in emergencies due to injury) for all equine/large animals, companions, exotic and mixed animal practices. For example, Wristscan V9, a diagnostic device, is being used for pregnancy tests for animals. In addition, the Alivecor iPhone app is used to perform electrocardiograms on animals for cardiologist review. Major companies in the veterinary medical equipment market include Carestream Health, IDEXX Laboratories Inc., Agfa Healthcare, MinXray Inc., and Diagnostic Imaging Systems. North America was the largest region in the veterinary medical equipment market in 2022. Asia-Pacific was the second-largest region in the veterinary medical equipment market. The regions covered in the veterinary medical equipment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary medical equipment market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The veterinary medical equipment market consists of sales of stethoscopes, ultrasounds, x-ray machines, sonography machines, and intravenous pumps. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary medical equipment market is segmented - 1) By Type: Veterinary Diagnostic Equipment, Veterinary Anesthesia Equipment, Veterinary Patient Monitoring Equipment, Other Veterinary Medical Equipment 2) By Product: Instruments/Equipment, Disposables 3) By Animal Type: Small Companion Animals, Large Animals, Other Animals 4) By End User: Veterinary Hospitals, Veterinary Clinics, Research Institutes

Veterinary anesthesia equipment refers to a type of device or instrument that is composed of a number of components that work together to support breathing and safely deliver inhalant anesthetic agents into patients' bodies to prevent pain or discomfort during surgical procedures. The main types of veterinary anesthesia equipment market are standalone anesthesia machines, portable anesthesia machines, which are used for small and large animals. The "standalone anesthesia machines" refer to the equipment that provides anesthesia to the animals. These are used in veterinary hospitals, veterinary clinics, emergency service centers, veterinary homecare settings. The veterinary anesthesia equipment research report is one of a series of new reports from The Business Research Company that provides veterinary anesthesia equipment statistics, including veterinary anesthesia equipment industry global market size, regional shares, competitors with veterinary anesthesia equipment share, detailed veterinary anesthesia equipment segments, market trends and opportunities, and any further data you may need to thrive in the veterinary anesthesia equipment industry. This veterinary anesthesia equipment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global veterinary anesthesia equipment market size will grow from $0.73 billion in 2022 to $0.78 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary anesthesia equipment market size is expected to grow from $1.03 billion in 2027 at a compound annual growth rate (CAGR) of 7.1%. The rising prevalence of oral diseases in dogs and cats is driving the market for veterinary anesthesia equipment used during oral examinations. Diagnosis and treatment of oral diseases. Dental cleaning requires pet animals to be under general anesthesia as it is difficult to handle animals when they are awake and conscious. According to the American Veterinary Dental College, periodontal disease is the most common clinical condition occurring in adult dogs and cats. Thus, the rising prevalence of oral diseases in pet animals is increasing the demand for veterinary anesthesia equipment driving the market growth. The high prices of veterinary anesthetic equipment are acting as a restraint on the market. It is expensive for small veterinary hospitals and clinics to buy and maintain anesthesia equipment, thereby limiting market penetration. The high price of the equipment can be attributed to the advanced technology used in the equipment. Manufacturers of veterinary anesthesia equipment are introducing products with advanced features to provide a safe and reliable treatment. The new products being introduced offer solutions to problems like power failure, battery failure or exhaustion, and failure of electronic components. Companies such as DRE veterinary and Supera have been investing in introducing anesthetic machines with safety features. Manufacturers of veterinary anesthesia equipment are required to adhere to stringent regulations set by various regulatory bodies. For instance, the US Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) regulates the market for veterinary devices in the USA. The FDA issues guidelines concerning the manufacturing, procuring, packaging, branding, selling, and usage of medical devices. Also, the FDA encourages veterinarians and pet owners to report defects in veterinary medical equipment. Major players in the veterinary anesthesia equipment market are JD medical, Midmark Corporation, Smiths Medical, Mindray Medical, Kent Scientific, Everest Veterinary Technology, Dispomed Ltd., Henry Schein Company, Mediquip, and Patterson Scientific. North America was the largest region in the veterinary anesthesia equipment market in 2022. Asia-Pacific was the second-largest region in the global veterinary anesthesia equipment market. The regions covered in the global veterinary anesthesia equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the veterinary anesthesia equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The veterinary anesthesia equipment market consists of sales of high-pressure anesthesia, intermediate pressure anesthesia, and low-pressure anesthesia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary anesthesia equipment market is segmented - 1) By Type: Standalone Anaesthesia Machines, Portable Anaesthesia Machines 2) By End User: Veterinary Hospitals, Veterinary Clinics, Emergency Service Centres, Veterinary Homecare Settings 3) By Animal Type: Small, Large

Veterinary pharmaceuticals are a class of drugs that are pharmacologically active and used to control, prevent, and treat diseases in animals. They have an effect when administered to animals and are rapidly broken down into active ingredients due to small intestine metabolism. The main types of veterinary pharmaceuticals include veterinary vaccines, veterinary antibiotics, veterinary parasiticides, and other types. Veterinary vaccines provide protection against one or more diseases, which can lower the severity or prevent certain diseases entirely. The routes of administration include oral and other routes of administration for animal types, including companion animals and livestock animals. The vaccines include inactivated vaccines, attenuated vaccines, and recombinant vaccines. The veterinary pharmaceuticals research report is one of a series of new reports from The Business Research Company that provides veterinary pharmaceuticals statistics, including veterinary pharmaceuticals industry global market size, regional shares, competitors with veterinary pharmaceuticals share, detailed veterinary pharmaceuticals segments, market trends and opportunities, and any further data you may need to thrive in the veterinary pharmaceuticals industry. This veterinary pharmaceuticals research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global veterinary pharmaceuticals market size will grow from $28.43 billion in 2022 to $30.2 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global veterinary pharmaceuticals market size is expected to grow from $37.12 billion in 2027 at a CAGR of 5.3%. The increase in the prevalence rate of diseases among animals serves as one of the major drivers for the veterinary pharmaceuticals market. The increase in the incidence of diseases in livestock and companion animals will require medicines to treat the animals for the diseases. For instance, according to the Banfield State of Pet Health Report, the prevalence of diabetes in dogs has increased by 79.7% from 13.1 cases per 10,000 to 23.6 cases whereas the prevalence rate increased by 18% in cats. The increase in the prevalence rate of diseases among animals results in an increased demand for veterinary pharmaceuticals. The veterinary pharmaceuticals market is being restrained by a lack of awareness about animal healthcare. According to the Animal Welfare Act 2006, proper healthcare means the pet should have regular vaccinations, a suitable diet, protection from pain and suffering, suffering and should be free from any kind of disease. According to the PDSA Animal Wellbeing (PAW) UK report, only 38% of people in the UK are aware of this legislation which shows a very less proportion of the population is aware of animal healthcare and acts as a major restraint for the market. The rise of generic drugs for animal care is being seen as the latest trend in the veterinary pharmaceuticals market. The economical nature of generic drugs enables pet lovers to take care of their pets efficiently. The FDA has approved 22 generic animal drugs for cats and dogs, which has increased the adoption of generic drugs by veterinarians. According to a survey conducted on 520 veterinarians by Brakke and Trone Brand Energy Inc., around 80% of the veterinarians confirmed that they are using generic drugs to save the pet owners’ money. However, the lower margin of profit given by generic drug manufacturers compared with the heavy margins of branded drugs needs to be looked into by veterinarians. The veterinary pharmaceuticals market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US Food and Drug Administration), and others. For instance, the EU agencies require 6 to 12 months to approve veterinary medicinal products. Moreover, it requires all parts of the registration dossier to be submitted together, unlike the US-FDA, which accepts phased submissions. The US-FDA assesses each technical section for 6 months which may be extended to another 6 month cycle if questions or concerns are raised. However, the technical sections’ assessment is done simultaneously, and therefore, the manufacturers should identify the time-consuming steps and plan the work accordingly and estimate the date of approval. Also, the license validity and renewal of the application in the EU region is very difficult upon the existing regulatory policies. Therefore, the manufacturers of veterinary pharmaceuticals should plan well, communicate effectively to minimize the costs and reduce timelines. Major players in the veterinary pharmaceuticals market are Merck & Co. Inc., Zoetis Inc., Eli Lilly and Company, Bayer AG, Boehringer Ingelheim GmbH, Perrigo Company PLC., Virbac SA, Dechra Pharmaceuticals PLC., CevaSanteAnimale, and Aratana Therapeutics. North America was the largest region in the veterinary pharmaceuticals market in 2022. Asia-Pacific was the second-largest region in the global veterinary pharmaceuticals market. The regions covered in the global veterinary pharmaceuticals report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary pharmaceuticals market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The veterinary pharmaceuticals market consists of sales of biological drugs, biosimilars, monoclonal antibodies, sedatives, and antihistaminic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global veterinary pharmaceuticals market is segmented - 1) By Type: Veterinary Vaccines, Veterinary Antibiotics, Veterinary Parasiticides, Other Types 2) By End User: Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores 3) By Route of Administration: Oral, Other Routes Of Administration 4) By Animal Type: Companion Animals, Livestock Animals 5) By Vaccines: Inactivated Vaccines, Attenuated Vaccines, Recombinant Vaccines